Taurus Vascular is one step closer to stopping abdominal aortic aneurysms for good. Photo courtesy of TNVC

A Houston biotech company has won the Texas A&M New Ventures Competition (TNVC). Taurus Vascular took home $30,000 for its first-place victory.

Taurus Vascular is working on a new solution to stopping abdominal aortic aneurysms (AAA) before they rupture and become potentially fatal. The company arose out of the TMC Innovation Biodesign Program. Fellows Matthew Kuhn and Melanie Lowther had a year to bring a company to fruition. The highly qualified team can boast of Kuhn’s more than 40 patents and Lowther’s former role as director of entrepreneurship and innovation at Texas Children’s Hospital.

The competition’s intense process included presenting to commercialization experts across several rounds. In fact, vetting takes four months and includes coaching to help competitors thrive in their pitches.

“As we celebrate the tenth year of the Texas A&M New Ventures Competition, we recognize the significant economic impact these startups have across Texas and their worldwide societal contributions,” says Chris Scotti, TNVC chair, in a news release. “Looking ahead, we are excited to continue fostering innovation and supporting science and engineering-based companies that drive progress and create lasting change.”

In its decade of competitions, TNVC has awarded almost $4 million prizes to startups. This year alone, 27 awards were distributed. Those included investment capital, consulting, legal and engineering services, and other types of support tailored to the winners’ needs.

“We are honored to have won first place at the Texas New Ventures Competition. Competing alongside so many outstanding companies and talented founders makes this recognition even more meaningful and reflects the dedication and hard work of our team at Taurus Vascular,” Kuhn says in a press release. “The financial support and increased visibility from this win will be pivotal for our growth, unlocking new opportunities and partnerships.

"This award strengthens our belief in our mission of reducing endoleak risks in endovascular aortic aneurysm repair and making a positive impact on patient care," he continues. "We are also grateful to Biotex for choosing us as a recipient for their sponsored prize and eagerly anticipate collaborating with them in the next phase of our technology’s development.”

Fewer than 20 percent of patients whose AAAs rupture survive. Kuhn told InnovationMap last year that he hopes to commercialize his technology by 2030. This competition brings patients closer to one day having far better odds when contending with a AAA.

A new innovation out of the Texas Medical Center's Biodesign Program is enhancing efficacy of a life-saving aortic aneurysm rupture procedure. Photo via Getty Images

Houston biodesign innovators ready to spin out startup with life-saving vascular tech

heartbreak healers

Yes, you can die of a broken heart — although it's not in the hyperbolic way you might be thinking. Fewer than 20 percent of people who have an aortic aneurysm rupture survive the event. But aortic aneurysms can be treated if they’re caught before they burst. A new Houston company is devoted to a novel solution to helping patients with abdominal aortic aneurysms (AAA).

That company is Taurus Vascular. As part of the current class of the TMC Innovation Biodesign Program, fellows Matthew Kuhn and Melanie Lowther were tasked with creating a biomedical company in a year. The founders started their journey last August. At the end of this month, they'll be kicked out of the nest, Kuhn tells InnovationMap. Taurus is also in Rice University's 2023 cohort of OwlSpark, an ongoing summer program for startups founders from the Rice community.

Kuhn is a biomedical engineer who just scored his forty-fifth patent. The CEO says that he hit it off quickly with his co-founder and COO, Lowther, former director entrepreneurship and innovation at Texas Children’s Hospital.

Matthew Kuhn and Melanie Lowther co-founded Taurus Vascular as TMC Biodesign fellows. Photos via taurusvascular.com

Members of the Biodesign Program are paid a livable stipend to devote themselves fully to creating a pioneering company. Kuhn says that he became interested in finding a more effective way to heal AAAs during his four and a half years as a project leader at the Center for Device Innovation at the Texas Medical Center.

“It was ripe for innovation and we landed on a concept of some merit,” he says.

The current standard of care for AAAs is EVAR, or endovascular aneurysm repair, in which a surgeon inserts a stent to relieve pressure on the aneurysm.

“It used to be if you had a AAA, you had a gnarly procedure,” he says, which included a large incision across the abdomen. EVAR eliminated that, but its problem is that it often results in endoleaks. As many as 20 percent of patients need another EVAR within five years.

Taurus Vascular’s technology improves on EVAR by placing a self-deploying stent to create a drainage pathway between the high-pressure aneurysm sac and a low-pressure nearby vein — mitigating the adverse impact of endoleaks that would otherwise cause the aneurysm to continue to grow. The simple solution will allow patients to live longer, healthier lives after their procedure.

Kuhn says that being in Houston has been and will continue to be instrumental in his company’s success. Part of that, of course, is his relatively cosseted status as a founder in the Innovation Biodesign Program. But he says that the industry as a whole has become almost like a family.

“It feels very different from startup life for other industries where it feels competitive,” he explains. "You have to be a little crazy to start a medical device company and there’s a sense that we’re all in the same boat. People are so generous with their time to share resources. I feels like I have 100 co-founders."

Following the end of Taurus Vascular’s time in the program that helped conceived it, its founders will remain in the same building, continuing to work to support their technology. The next step is raising a seed round that will pay for the company’s chronic animal studies. Because Taurus Vascular is producing a Class III medical device, its approval process to get to market is the most stringent the FDA has.

The goal is to be commercial by 2030, says Kuhn. By then, Taurus Vascular will have healed many a heart.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston students develop cost-effective glove to treat Parkinson's symptoms

smart glove

Two Rice undergraduate engineering students have developed a non-invasive vibrotactile glove that aims to alleviate the symptoms of Parkinson’s disease through therapeutic vibrations.

Emmie Casey and Tomi Kuye developed the project with support from the Oshman Engineering Design Kitchen (OEDK) and guidance from its director, Maria Oden, and Rice lecturer Heather Bisesti, according to a news release from the university.

The team based the design on research from the Peter Tass Lab at Stanford University, which explored how randomized vibratory stimuli delivered to the fingertips could help rewire misfiring neurons in the brain—a key component of Parkinson’s disease.

Clinical trials from Stanford showed that coordinated reset stimulation from the vibrations helped patients regain motor control and reduced abnormal brain activity. The effects lasted even after users removed the vibrotactile gloves.

Casey and Kuye set out to replicate the breakthrough at a lower cost. Their prototype replaced the expensive motors used in previous designs with motors found in smartphones that create similar tiny vibrations. They then embedded the motors into each fingertip of a wireless glove.

“We wanted to take this breakthrough and make it accessible to people who would never be able to afford an expensive medical device,” Casey said in the release. “We set out to design a glove that delivers the same therapeutic vibrations but at a fraction of the cost.”

Rice’s design also targets the root of the neurological disruption and attempts to retrain the brain. An early prototype was given to a family friend who had an early onset of the disease. According to anecdotal data from Rice, after six months of regularly using the gloves, the user was able to walk unaided.

“We’re not claiming it’s a cure,” Kuye said in the release. “But if it can give people just a little more control, a little more freedom, that’s life-changing.”

Casey and Kuye are working to develop a commercial version of the glove priced at $250. They are taking preorders and hope to release 500 pairs of gloves this fall. They've also published an open-source instruction manual online for others who want to try to build their own glove at home. They have also formed a nonprofit and plan to use a sliding scale price model to help users manage the cost.

“This project exemplifies what we strive for at the OEDK — empowering students to translate cutting-edge research into real-world solutions,” Oden added in the release. “Emmie and Tomi have shown extraordinary initiative and empathy in developing a device that could bring meaningful relief to people living with Parkinson’s, no matter their resources.”

New Austin tower eclipses Houston landmark as Texas' tallest building

Tallest in Texas

Texas officially has a new tallest tower. The title moves from Houston, for the JPMorgan Chase Tower, to Austin, for Waterline at 98 Red River St. The new tower will contain mixed-use spaces including apartments, offices, a hotel, restaurants, and retail. It is scheduled to open in full in 2026.

Waterline held a "topping out" ceremony in August, when the final beam was added to the top of the tower. It now reaches 74 stories and 1,025 feet — just 23 feet taller than the JPMorgan Chase Tower.

Waterline height comparison Waterline is now the tallest building in Texas.Graphic courtesy of Lincoln Property Company

According to a press release, hundreds of construction workers and team project members attended the Waterline ceremony, and more than 4,750 people have worked on it since the project broke ground in 2022. An estimated 875 people were working onsite every day at the busiest time for construction.

The Waterline site is on a 3.3-acre campus with lots of views of Waller Creek and Lady Bird Lake. The building contains space for 352 luxury apartments, 700,000 square feet of offices, a hotel called 1 Hotel Austin with 251 rooms, and 24,000 square feet of retail stores and restaurants.

The only space that is open to new tenants already is the office space, with residential soon to follow. The hotel and residential units are expected to open in fall 2026.

Waterline tower Austin A view from above, shot by drone.Photo courtesy of Lincoln Property Company and Kairoi Residential

“Seamlessly integrated with Waller Creek, Waterloo Greenway and the hike-and-bike trail around Lady Bird Lake, Waterline will quickly become a top downtown destination and activity center," said Lincoln executive vice president Seth Johnston in a press release. Project improvements will also make it far easier for people to access all of the public amenities in this area from Rainey Street, the new Austin Convention Center, and the rest of the Central Business District."

---

This article originally appeared on CultureMap.com.